{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:05:45Z","timestamp":1790888745294,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alzheimer\u2019s Disease (AD) is the mostcommon cause of dementia, a neurological disorder characterized by memory loss and judgment impairment. Hyperlipidemia, a commonly co-occurring condition, should be treated to prevent associated complications. Medication adherence may be difficult for individuals with AD due to the complexity of AD management. Comprehensive Medication Reviews (CMRs), a required component of Medicare Part D Medication Therapy Management (MTM), have been shown to improve medication adherence. However, many MTM programs do not target AD. Additionally, racial\/ethnic disparities in MTM eligibility have been revealed. Thus, this study examined the effects of CMR receipt on reducing racial\/ethnic disparities in the likelihood of nonadherence to hyperlipidemia medications (statins) among the AD population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study used 2015-2017 Medicare data linked to the Area Health Resources Files. The likelihood of nonadherence to statin medications across racial\/ethnic groups was compared between propensity-score-matched CMR recipients and non-recipients in a ratio of 1 to 3. A difference-in-differences method was utilized to determine racial\/ethnic disparity patterns using a logistic regression by including interaction terms between dummy variables for CMR receipt and each racial\/ethnic minority group (non-Hispanic Whites, or Whites, as reference).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 623,400 Medicare beneficiaries. Blacks and Hispanics had higher statin nonadherence than Whites: Compared to Whites, Blacks\u2019 nonadherence rate was 4.53% higher among CMR recipients and 7.35% higher among non-recipients; Hispanics\u2019 nonadherence rate was 2.69% higher among CMR recipients and 7.38% higher among non-recipients. Differences in racial\/ethnic disparities between CMR recipients and non-recipients were significant for each minority group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) except Others. The difference between Whites and Hispanics in the odds of statin nonadherence was 11% lower among CMR recipients compared to non-recipients (OR\u2009=\u20090.89; 95% Confidence Interval\u2009=\u20090.85-0.94 for the interaction term between dummy variables for CMR and Hispanics). Interaction terms between dummy variables for CMR and other racial\/ethnic minorities were not significant. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Receiving a CMR was associated with a disparity reduction in nonadherence to statin medications between Hispanics and Whites among patients with AD. Strategies need to be explored to increase the number of MTM programs that target AD and promote CMR completion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-07483-8","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T22:02:35Z","timestamp":1644271355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Medicare comprehensive medication review on racial\/ethnic disparities in nonadherence to statin medications among patients with Alzheimer\u2019s Disease: an observational analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jamie A.","family":"Browning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chun Steve","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim Y.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A.","family":"Chisholm-Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"7483_CR1","doi-asserted-by":"publisher","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460. https:\/\/doi.org\/10.1002\/alz.12068.","DOI":"10.1002\/alz.12068"},{"key":"7483_CR2","unstructured":"Centers for Disease Control and Prevention. CDC wonder: about underlying cause of death, 1999-2019. https:\/\/wonder.cdc.gov\/UCD-ICD10.html. Accessed 16 Aug 2021."},{"key":"7483_CR3","volume-title":"2017 national population projections tables: main series","author":"United States Census Bureau","year":"2020","unstructured":"United States Census Bureau. 2017 national population projections tables: main series. 2020. https:\/\/www.census.gov\/data\/tables\/2017\/demo\/popproj\/2017-summary-tables.html. Accessed 16 Aug 2021."},{"issue":"19","key":"7483_CR4","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778\u201383. https:\/\/doi.org\/10.1212\/WNL.0b013e31828726f5.","journal-title":"Neurology"},{"issue":"Suppl 13","key":"7483_CR5","first-page":"S356","volume":"17","author":"RG Stefanacci","year":"2011","unstructured":"Stefanacci RG. The costs of Alzheimer\u2019s disease and the value of effective therapies. Am J Manag Care. 2011;17(Suppl 13):S356\u201362.","journal-title":"Am J Manag Care"},{"issue":"9046","key":"7483_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0140-6736(96)09328-2","volume":"349","author":"A Hofman","year":"1997","unstructured":"Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer\u2019s disease in the Rotterdam study. Lancet. 1997;349(9046):151\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(96)09328-2.","journal-title":"Lancet"},{"key":"7483_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnagi.2020.00005","volume":"12","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Liang Y, Zhang X, Xu J, Lin J, Zhang R, et al. Low-density lipoprotein cholesterol and Alzheimer\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2020;12:5. https:\/\/doi.org\/10.3389\/fnagi.2020.00005.","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"7483_CR8","doi-asserted-by":"publisher","first-page":"e12008","DOI":"10.7759\/cureus.12008","volume":"12","author":"M Agarwal","year":"2020","unstructured":"Agarwal M, Khan S. Plasma lipids as biomarkers for Alzheimer\u2019s disease: a systematic review. Cureus. 2020;12(12):e12008. https:\/\/doi.org\/10.7759\/cureus.12008.","journal-title":"Cureus"},{"issue":"6","key":"7483_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/brainsci10060386","volume":"10","author":"O S\u00e1iz-Vazquez","year":"2020","unstructured":"S\u00e1iz-Vazquez O, Puente-Mart\u00ednez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santab\u00e1rbara J. Cholesterol and Alzheimer\u2019s disease risk: a meta-meta-analysis. Brain Sci. 2020;10(6):386. https:\/\/doi.org\/10.3390\/brainsci10060386.","journal-title":"Brain Sci"},{"key":"7483_CR10","volume-title":"Medicare program; contract year 2015 policy and technical changes to the Medicare advantage and the Medicare prescription drug benefit programs","author":"Department of Health & Human Services, Centers for Medicare & Medicaid Services","year":"2014","unstructured":"Department of Health & Human Services, Centers for Medicare & Medicaid Services. Medicare program; contract year 2015 policy and technical changes to the Medicare advantage and the Medicare prescription drug benefit programs: Federal Register; 2014. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2014-01-10\/pdf\/2013-31497.pdf. Accessed 16 Aug 2021"},{"key":"7483_CR11","volume-title":"CY 2015 medication therapy management program guidance and submission instructions","author":"Center for Medicare","year":"2014","unstructured":"Center for Medicare. CY 2015 medication therapy management program guidance and submission instructions: Department of Health & Human Services, Centers for Medicare & Medicaid Services; 2014. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/MemoContractYear2015MedicationTherapyManagementProgramSubmission050714.pdf. Accessed 16 Aug 2021"},{"key":"7483_CR12","unstructured":"Medication Therapy Management. Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/MTM. Accessed 16 Aug 2021."},{"issue":"6","key":"7483_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.18553\/jmcp.2019.25.6.688","volume":"25","author":"E Ferries","year":"2019","unstructured":"Ferries E, Dye JT, Hall B, Ndehi L, Schwab P, Vaccaro J. Comparison of Medication Therapy Management services and their effects on health care utilization and medication adherence. J Manag Care Spec Pharm. 2019;25(6):688\u201395. https:\/\/doi.org\/10.18553\/jmcp.2019.25.6.688.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"7483_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.18549\/PharmPract.2017.03.1026","volume":"15","author":"DA Erku","year":"2017","unstructured":"Erku DA, Ayele AA, Mekuria AB, Belachew SA, Hailemeskel B, Tegegn HG. The impact of pharmacist-led medication therapy management on medication adherence in patients with type 2 diabetes mellitus: a randomized controlled study. Pharm Pract (Granada). 2017;15(3):1026. https:\/\/doi.org\/10.18549\/PharmPract.2017.03.1026.","journal-title":"Pharm Pract (Granada)"},{"issue":"5","key":"7483_CR15","first-page":"243","volume":"12","author":"C Gray","year":"2019","unstructured":"Gray C, Cooke CE, Brandt N. Evolution of the Medicare Part D Medication Therapy Management program from inception in 2006 to the present. Am Health Drug Benefits. 2019;12(5):243\u201351.","journal-title":"Am Health Drug Benefits"},{"key":"7483_CR16","volume-title":"2017 Medicare part D medication therapy management (MTM) programs","author":"Centers for Medicare & Medicaid Services","year":"2017","unstructured":"Centers for Medicare & Medicaid Services. 2017 Medicare part D medication therapy management (MTM) programs. 2017. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/CY2017-MTM-Fact-sheet.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR17","volume-title":"2019 Medicare part D medication therapy management (MTM) programs","author":"Centers for Medicare & Medicaid Services","year":"2019","unstructured":"Centers for Medicare & Medicaid Services. 2019 Medicare part D medication therapy management (MTM) programs. 2019. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/CY2019-MTM-Fact-Sheet.pdf. Accessed 16 Aug 2021."},{"issue":"4","key":"7483_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jphs.12142","volume":"7","author":"J Wang","year":"2016","unstructured":"Wang J, Qiao Y, Spivey CA, Li C, Clark C, Deng Y, et al. Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. J Pharm Health Serv Res. 2016;7(4):209\u201315. https:\/\/doi.org\/10.1111\/jphs.12142.","journal-title":"J Pharm Health Serv Res"},{"key":"7483_CR19","unstructured":"Health Resources & Services Administration Data Warehouse. Area health resources files. https:\/\/data.hrsa.gov\/topics\/health-workforce\/ahrf. Accessed 16 Aug 2021."},{"key":"7483_CR20","unstructured":"Research Data Assistance Center. Data file search. https:\/\/www.resdac.org\/cms-data?tid_1%5B%5D=1. Accessed 16 Aug 2021."},{"key":"7483_CR21","unstructured":"Research Data Assistance Center. Medicare Master Beneficiary Summary File (MBSF) Base. https:\/\/www.resdac.org\/cms-data\/files\/mbsf-base. Accessed 16 Aug 2021."},{"key":"7483_CR22","unstructured":"Chronic Conditions Data Warehouse. Condition categories. https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories. Accessed 16 Aug 2021."},{"key":"7483_CR23","unstructured":"Research Data Assistance Center. Part D event (PDE) file. https:\/\/www.resdac.org\/cms-data\/files\/pde. Accessed 16 Aug 2021."},{"key":"7483_CR24","unstructured":"Research Data Assistance Center. Part D medication therapy management data file. https:\/\/www.resdac.org\/cms-data\/files\/part-d-mtm. Accessed 16 Aug 2021."},{"key":"7483_CR25","unstructured":"Health Insurance Marketplace. 2017 quality rating system measure technical specifications. In: Quality initiatives - general information. Centers for Medicare & Medicaid Services; 2016. https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/QualityInitiativesGenInfo\/Downloads\/2017_QRS-Measure_Technical_Specifications.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR26","unstructured":"Health Insurance Exchange. 2018 quality rating system measure technical specifications. In: quality initiatives \u2013 general information. Centers for Medicare & Medicaid Services; 2017. https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/QualityInitiativesGenInfo\/Downloads\/Revised_QRS-2018-Measure-Tech-Specs_20170929_508.pdf. Accessed 16 Aug 2021."},{"issue":"1","key":"7483_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355. https:\/\/doi.org\/10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"issue":"6","key":"7483_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057\u201369. https:\/\/doi.org\/10.1002\/sim.6004.","journal-title":"Stat Med"},{"key":"7483_CR29","unstructured":"Center for Medicare. CY 2016 medication therapy management program guidance and submission instructions. Department of Health & Human Services, Centers for Medicare & Medicaid Services; 2015. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/Memo-Contract-Year-2016-Medication-Therapy-Management-MTM-Program-Submission-v-040715.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR30","unstructured":"Center for Medicare. CY 2017 medication therapy management program guidance and submission instructions. Department of Health & Human Services, Centers for Medicare & Medicaid Services; 2016. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/Memo-Contract-Year-2017-Medication-Therapy-Management-MTM-Program-Submission-v-040816.pdf. Accessed 16 Aug 2021."},{"issue":"2","key":"7483_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.18553\/jmcp.2007.13.2.142","volume":"13","author":"GW Daniel","year":"2007","unstructured":"Daniel GW, Malone DC. Characteristics of older adults who met the annual prescription drug expenditure threshold for Medicare medication therapy management programs. J Manag Care Pharm. 2007;13(2):142\u201354. https:\/\/doi.org\/10.18553\/jmcp.2007.13.2.142.","journal-title":"J Manag Care Pharm"},{"key":"7483_CR32","volume-title":"2015 medicare part D medication therapy management (MTM) programs","author":"Centers for Medicare & Medicaid Services","year":"2015","unstructured":"Centers for Medicare & Medicaid Services. 2015 medicare part D medication therapy management (MTM) programs. 2015. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/CY2015-MTM-Fact-Sheet.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR33","volume-title":"2016 Medicare part D medication therapy management (MTM) programs","author":"Centers for Medicare & Medicaid Services","year":"2016","unstructured":"Centers for Medicare & Medicaid Services. 2016 Medicare part D medication therapy management (MTM) programs. 2016. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/CY2016-MTM-Fact-Sheet.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR34","unstructured":"Centers for Medicare & Medicaid Services. Part C and D performance data. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovGenIn\/PerformanceData. Accessed 16 Aug 2021."},{"issue":"6","key":"7483_CR35","first-page":"1273","volume":"34","author":"L Gelberg","year":"2000","unstructured":"Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273\u2013302.","journal-title":"Health Serv Res"},{"key":"7483_CR36","unstructured":"Centers for Medicare & Medicaid Services. Chapter 7 - Risk adjustment. In: Medicare managed care manual. https:\/\/www.cms.gov\/Regulations-and-Guidance\/Guidance\/Manuals\/Downloads\/mc86c07.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR37","unstructured":"Pharmacy Quality Solutions. PQS summary of 2021 Medicare part C and D star ratings technical notes. https:\/\/www.pharmacyquality.com\/wp-content\/uploads\/2020\/10\/PQSMedicareStarRatingsUpdate2021NEW.pdf. Accessed 16 Aug 2021."},{"key":"7483_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.trci.2018.08.009","volume":"4","author":"C Chen","year":"2018","unstructured":"Chen C, Zissimopoulos JM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimers Dement (N Y). 2018;4:510\u201320. https:\/\/doi.org\/10.1016\/j.trci.2018.08.009.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"7483_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/JGP.0b013e3181f7d881","volume":"19","author":"MG Livney","year":"2011","unstructured":"Livney MG, Clark CM, Karlawish JH, Cartmell S, Negr\u00f3n M, Nu\u00f1ez J, et al. Ethnoracial differences in the clinical characteristics of Alzheimer\u2019s disease at initial presentation at an urban Alzheimer\u2019s disease center. Am J Geriatr Psychiatry. 2011;19(5):430\u20139. https:\/\/doi.org\/10.1097\/JGP.0b013e3181f7d881.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"7483_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","volume":"85","author":"LL Barnes","year":"2015","unstructured":"Barnes LL, Leurgans S, Aggarwal NT, Shah RC, Arvanitakis Z, James BD, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000001834.","journal-title":"Neurology"},{"issue":"4","key":"7483_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HCO.0000000000000874","volume":"36","author":"CC Diaconu","year":"2021","unstructured":"Diaconu CC, Iorga RA, Furtunescu F, Katsiki N, Stoian AP, Rizzo M. Statin intolerance: new data and further options for treatment. Curr Opin Cardiol. 2021;36(4):487\u201393. https:\/\/doi.org\/10.1097\/HCO.0000000000000874.","journal-title":"Curr Opin Cardiol"},{"issue":"8","key":"7483_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamacardio.2018.1511","volume":"3","author":"MG Nanna","year":"2018","unstructured":"Nanna MG, Navar AM, Zakroysky P, Xiang Q, Goldberg AC, Robinson J, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry. JAMA Cardiol. 2018;3(8):739. https:\/\/doi.org\/10.1001\/jamacardio.2018.1511.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"7483_CR43","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/gerona\/glaa236","volume":"76","author":"B Downer","year":"2021","unstructured":"Downer B, Al Snih S, Chou L-N, Kuo Y-F, Raji M, Markides KS, et al. Changes in health care use by Mexican American Medicare beneficiaries before and after a diagnosis of dementia. Newman AB, editor. J Gerontol Ser A Biol Med Sci. 2021;76(3):534\u201342. https:\/\/doi.org\/10.1093\/gerona\/glaa236.","journal-title":"J Gerontol Ser A Biol Med Sci"},{"issue":"11","key":"7483_CR44","doi-asserted-by":"publisher","first-page":"e006105","DOI":"10.1161\/JAHA.117.006105","volume":"6","author":"BM Egan","year":"2017","unstructured":"Egan BM, Li J, Sarasua SM, Davis RA, Fiscella KA, Tobin JN, et al. Cholesterol control among uninsured adults did not improve from 2001-2004 to 2009-2012 as disparities with both publicly and privately insured adults doubled. J Am Heart Assoc. 2017;6(11):e006105. https:\/\/doi.org\/10.1161\/JAHA.117.006105.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"7483_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.18553\/jmcp.2014.20.8.834","volume":"20","author":"JE Couto","year":"2014","unstructured":"Couto JE, Panchal JM, Lal LS, Bunz TJ, Maesner JE, O\u2019Brien T, et al. Geographic variation in medication adherence in commercial and Medicare part D populations. J Manag Care Spec Pharm. 2014;20(8):834\u201342. https:\/\/doi.org\/10.18553\/jmcp.2014.20.8.834.","journal-title":"J Manag Care Spec Pharm"},{"key":"7483_CR46","doi-asserted-by":"publisher","first-page":"113443","DOI":"10.1016\/j.socscimed.2020.113443","volume":"268","author":"CE Miller","year":"2021","unstructured":"Miller CE, Vasan RS. The southern rural health and mortality penalty: a review of regional health inequities in the United States. Soc Sci Med. 2021;268:113443. https:\/\/doi.org\/10.1016\/j.socscimed.2020.113443.","journal-title":"Soc Sci Med"},{"issue":"3 Pt 2","key":"7483_CR47","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/j.1475-6773.2012.01411.x","volume":"47","author":"AM Zaslavsky","year":"2012","unstructured":"Zaslavsky AM, Ayanian JZ, Zaborski LB. The validity of race and ethnicity in enrollment data for Medicare beneficiaries. Health Serv Res. 2012;47(3 Pt 2):1300\u201321. https:\/\/doi.org\/10.1111\/j.1475-6773.2012.01411.x.","journal-title":"Health Serv Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07483-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-07483-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07483-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T22:02:53Z","timestamp":1644271373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-07483-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7483"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-07483-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Tennessee Health Science Center Institutional Review Board (approval number: #20-07197-XM). Informed consent is not applicable for this analysis. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAB, CCST, XD, JYW, CKF, JWT, and CL: None. MAC: Received funding from Carlos and Marguerite Mason Trust. JW: Received funding from AbbVie, Curo, Bristol Myers Squibb, Pfizer, and Pharmaceutical Research and Manufacturers of America (PhRMA), and serves on Health Outcomes Research Advisor Committee of the PhRMA Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}